ResearcherInsermNo recent work listed
Svitlana P. Grekova
Matched on OpenAlex author ID A5029611698, A5079122246. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2011: 2 papers · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper
Papers 6
- Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Co-author DOI 10.3390/v13061019↗
- Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24312↗
- Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. First author DOI 10.1002/ijc.28597↗
- Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. First author DOI 10.1128/jvi.03688-13↗
- Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. Co-author DOI 10.1155/2011/741868↗
- Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Co-author DOI 10.4161/cbt.12.10.17678↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nathalia A. Giese · 5 shared papers, 2011–2021 · strength 0.30
- Paper Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreat… DOI 10.3390/v13061019↗
- Paper Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer. DOI 10.18632/oncotarget.24312↗
- Paper Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabin… DOI 10.1002/ijc.28597↗
- Zahari Raykov · 4 shared papers, 2011–2014 · strength 0.14
- Paper Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabin… DOI 10.1002/ijc.28597↗
- Paper Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. DOI 10.1155/2011/741868↗
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- M. Neulinger · 1 shared paper, 2021 · strength 0.12
- Michael Volkmar · 1 shared paper, 2021 · strength 0.12
- Elisa Espinet · 1 shared paper, 2021 · strength 0.12
- Miriam Schenk · 1 shared paper, 2021 · strength 0.12
- Marc Aprahamian · 3 shared papers, 2011–2014 · strength 0.11
- Paper Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabin… DOI 10.1002/ijc.28597↗
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Assia L. Angelova · 3 shared papers, 2011–2014 · strength 0.10
- Paper Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. DOI 10.1155/2011/741868↗
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Verena M. Throm · 1 shared paper, 2018 · strength 0.07
- Klaus Felix · 1 shared paper, 2018 · strength 0.07
- Thilo Hackert · 1 shared paper, 2018 · strength 0.07
- Andrea S. Bauer · 1 shared paper, 2018 · strength 0.07
- Matthias M. Gaida · 1 shared paper, 2018 · strength 0.07
- Oliver Strobel · 1 shared paper, 2018 · strength 0.07
- Jens Werner · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.